Phenoptin
Phase 2Small molecule
BioMarin PharmaceuticalPhenoptin is one of 4 small molecule programs targeting Hyperphenylalaninemia. It is currently in Phase 2.
1
Indications
1
Total Trials
0
Active Trials
3
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
3 competitors in Hyperphenylalaninemia
#DrugCompanyPhaseTrials
1Kuvan
BioMarin PharmaceuticalPreclinical
Kuvan
BioMarin PharmaceuticalPreclinical
PTC923
PPTC Therapeutics
Phase 2
Phenoptin
BioMarin PharmaceuticalPhase 2
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Phenoptin. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 2[1]
- Company